LB Pharmaceuticals Inc (LBRX)

NASDAQ: LBRX · USD

$39.9

+0.24 (+0.6%)· Recorded snapshot

Market cap	1.3B
Net income (ttm)	-85.7M
EPS (ttm)	-$3.81
Shares out	32.3M
Volume	168,813

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -85.7M
EPS (ttm): -$3.81
Market cap: 1.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-50

P25 -113.8P50 -46.5P75 -0.9

ROIC-32.5

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All LBRX indicators

Market & fundamental data

Available fields

162

Groups with data

Currency

USD

Showing 162 of 162 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001691082
Company name	LB Pharmaceuticals Inc
Country	United States
Country code	US
CUSIP number	50180M108
Earnings date	2026-11-09
Earnings time	bmo
Employees	49
Enterprise value	$963.9M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2025-09-11
Is primary listing	Yes
Is SPAC	No
ISIN number	US50180M1080
Last 10-K release date	2026-03-26
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.3B
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$39.88
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	LBRX
U.S. state	New York
Website	https://lbpharma.us

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-9.56%
FCF / EV yield	-8.58%
FCF yield	-6.43%
P/B ratio	3.42x
Price / tangible book value	3.88x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.7M
ROA	-29.98%
ROCE	-27.02%
ROE	-50%
ROIC	-32.48%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-435,000
Depreciation and amortization	$345,000
EBIT	$-91.4M
EBITDA	$-91M
EPS	$-3.81
FCF per share	$-2.57
Financing cash flow	$396.4M
Free cash flow	$-82.8M
Free cash flow minus SBC	$-93.5M
Income taxes	$1,000
Investing cash flow	$-44.8M
Net cash flow	$269.2M
Net income	$-85.7M
Operating cash flow minus SBC	$-93.1M
Operating income	$-91.4M
Stock-based compensation	$10.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$11.59
Debt / equity	0.02
Long-term assets	$6.4M
Long-term liabilities	$5.8M
Net cash (debt)	$322.6M
Net cash / market cap	25.03%
Net cash growth	2,982.69%
Net debt / equity	-0.97
Piotroski F-Score	2
Property, plant and equipment	$5.6M
Shareholders' equity	$332.3M
Tangible book value	$332.3M
Tangible book value per share	$11.59
Total assets	$361.7M
Total cash	$327.8M
Total debt	$5.2M
Total liabilities	$29.3M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$355.3M
Current liabilities	$23.6M
Current ratio	15.08
Net working capital	$4.8M
Quick ratio	13.91
Working capital	$331.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-8,821.45%
Dividend yield	0%
Shareholder yield	-8,821.45%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$35.37
1D price change	0.61%
1M price change	5.87%
1M total return	5.87%
1W price change	-3.61%
1W total return	-3.61%
1Y price change	136.65%
1Y return CAGR	136.79%
1Y total return	136.65%
20-day SMA	$37.15
200-day SMA	$32.37
3M price change	13.63%
3M total return	13.63%
50-day SMA	$41.70
50-day SMA vs 200-day SMA	50over200
52-week high	$50.16
52-week high date	2026-08-25
52-week low	$14.32
52-week low date	2025-11-11
6M price change	24.24%
6M total return	24.24%
All-time high	$50.16
All-time high date	2026-08-25
All-time low	$13.36
All-time low date	2025-09-26
Average true range (ATR)	$2.32
Average volume	408.2K
Beta (1Y)	1.79
Beta (2Y)	1.56
Change from 52-week high	-20.49%
Change from 52-week low	178.55%
Change from all-time high	-21.21%
Change from all-time low	195.81%
Change from open	-0.85%
Day's gap	1.46%
Dollar volume	$6.7M
High price	$40.22
Low price	$39.42
Monthly RSI	0
Open price	$40.22
Position in 52-week range	57.5%
Previous close	$39.64
Price vs 150-day SMA	11.73%
Price vs 20-day SMA	6.38%
Price vs 200-day SMA	22.09%
Price vs 50-day SMA	-5.22%
Relative volume	0.41
Return from IPO open	110.22%
Return from IPO price	166.28%
RSI	52.65
Sharpe ratio	1.61
Sortino ratio	2.9
Volume	168.8K
Weekly RSI	56.93
YTD price change	77.54%
YTD total return	77.54%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26.5M
Float percentage	82.02%
Shares change (QoQ)	6.71%
Shares change (YoY)	8,821.45%
Shares held by insiders	0.73%
Shares held by institutions	83.46%
Shares outstanding	32.3M
Short % of float	22.72%
Short % of shares	18.63%
Short ratio	17.3 days

Deeper analysis on LBRX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this LBRX report

Is a complete LBRX research report available?

No complete published report is available for LB Pharmaceuticals Inc (LBRX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

LB Pharmaceuticals Inc (LBRX)

Price

Financial snapshot

Fair-value bridge

Latest news · LBRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All LBRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on LBRX

Frequently asked questions